去甲长春花碱加顺铂治疗晚期非小细胞肺癌42例

目的观察抗肿瘤新药去甲长春花碱（Ｎａｖｅｌｂｉｎｅ,ＮＶＢ）加顺铂（Ｃｉｓｐｌａｔｉｎ,ＤＤＰ）联合化疗治疗晚期非小细胞肺癌（Ｎｏｎｓｍａｌｃｅｌｌｕｎｇｃａｎｃｅｒ,ＮＳＣＬＣ）的疗效。方法治疗ＮＳＣＬＣ４２例。男性３３例,女性９例。病理类型以腺癌为主（２７例）,ⅢＢ期１７例,Ⅳ期２５例。２４例初治,１８例复治。结果部分缓解（ＰＲ）２０例,稳定（Ｓ）１８例,进展（Ｐ）４例,总有效率４７．６％。每周ＮＶＢ≥２５ｍｇ／ｍ２的有效率为５４．２％,＜２５ｍｇ／ｍ２的有效率３８．９％。中位缓解期３．３个月,中位生存期８．５个月。ＮＶＢ的剂量限制毒性为骨髓抑制,白细胞下降占１００．０％,其中Ⅲ、Ⅳ度为６６．６％。注射局部静脉毒性发生率４０．５％。结论以ＮＶＢ为主的联合化疗治疗晚期ＮＳＣＬＣ有效率高,毒性可以耐受,是一个有前途的抗肿瘤新药。

Navelbine plus cisplatin combination therapy in the treatment of advanced non-small cell lung cancer: a report of 42 cases

OBJECTIVE: To evaluate the results of combination chemotheray with navelbine (NVB) plus cisplatin (DDP) in the treatment of non-small cell lung cancer (NSCLC). METHODS: From 1992 through 1996, 42 patients with advanced NSCLC were enrolled in this study. The median age of the patients was 57 years. Adenocarcinoma was the most common type of malignancy. Seventeen patients had stage IIIB disease and 25 had stage IV. Twenty-four patients had no prior chemotherapy and 18 received previous chemotherapy. RESULTS: Partial response was observed in 20 patients with an overall response rate of 47.6%. The response appeared to correlate with dose intensity, as 54.2% response rate was achieved with a dose of NVB > or = 25 mg/m2/wk versus 38.9% response rate with NVB < 25 mg/m2/wk. The median response duration was 3.3 months and the median survival period was 8.5 months. The dose limiting toxicity was neutropenia which was seen in all treated cases (66.6% in grades III and IV). The local venous toxicity was observed in 40.5% of the patients. CONCLUSION: A high response rate was obtained in advanced NSCLC treated by NVB plus DDP. NVB is a promising antitumor agent with tolerable toxicity.